Inclusion Criteria:  age 18-70; signed inform consent; patients with recurrent malignant glioma; have received surgery, radiotherapy, chemotherapy; patients' tumor tissue should have a high mutation load(>10 TMB); be genetically unstable; at least have 10 neoantigens; should be able to provide tumor tissue and peripheral blood for sequencing and flow cytometry analysis; at least three months post last operation; one month after the completion of the last anti-drug therapy or radiotherapy; have not received any immune therapy; at least have one measurable lesion; KPS >60; estimated survival > 3 months patients should have adequate organ and bone marrow function;  Exclusion Criteria:  female patient is breastfeeding or pregnant; known history of allergy to peptides or other stimulating factors (i.e. GM-CSF); known history of Graft-Versus-Host Disease (GVHD); participation in gene therapy; other malignancy; systemic disease: i.e., severe infection; HIV; other conditions upon investigator's judgement;